Navigation Links
Post-Chemo Treatment May Boost Lung Cancer Survival
Date:5/20/2010

Study finds some benefit with erlotinib for people with non-small-cell form of disease

THURSDAY, May 20 (HealthDay News) -- Among people with non-small-cell lung cancer, treatment with the drug erlotinib (Tarceva) after chemotherapy appears to slightly boost survival rates, a new study suggests.

Non-small-cell lung cancer makes up about 85 percent of lung cancer cases. About half the time, people have advanced disease when diagnosed and are treated solely with chemotherapy, usually platinum-based chemo. But chemotherapy only boosts survival by eight to 10 months, the study authors noted.

The study findings, which support the use of erlotinib as a "maintenance" treatment, are based on research by Dr. Federico Cappuzzo of the Civil Hospital of Livorno in Italy and his colleagues. The researchers tested the drug in 889 people who'd had chemotherapy and whose disease had not gotten worse. They were randomly assigned to take erlotinib an inactive placebo.

According to the study, published online May 19 in The Lancet Oncology, the drug improved overall survival, compared with the placebo (12 months versus 11 months). The length of time without the disease progressing also was somewhat better for those who took the drug: 12 rather than 11 weeks. Most people tolerated the drug well, with skin rash and diarrhea being the most common side effect, the study found, but serious side effects affected 11 percent of those who took the drug, compared with 8 percent of those taking the placebo.

"The acceptable tolerability profile of erlotinib, together with proven efficacy in all patient subgroups and oral dosing, distinguishes erlotinib from other agents in this setting and could provide greater treatment choice for clinicians," the researchers concluded.

More information

The American Cancer Society has details about non-small-cell lung cancer.



-- Randy Dotinga



SOURCE: The Lancet Oncology, news release, May 19, 2010


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Book Delivers Latest ADHD Research, Treatments & Results
2. Early Treatment With Clot-Busting Drug Best After Stroke
3. CIGNA and Cancer Treatment Centers of America Reach New Agreement
4. New hope for better treatment for a rising cancer
5. Passages to Recovery Outdoor Addiction Treatment Program Achieves Joint Commission Accreditation
6. New technology aids in prostate cancer treatment
7. Impotence Drugs May Aid Brain Tumor Treatment
8. Self-directed behavioral IBS treatment rapidly relieves even the most severe symptoms
9. Researchers discover new way to rescue treatment sensitivity of breast cancer cells
10. Smarter use of existing treatment helps dramatically boost survival of young AML patients
11. Med Spa Treatments Become More Popular as Unemployment Rates Climb
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... The 9th annual meeting of ... (WMIC), will be held in New York City, NY on September 7 – ... congress will highlight and emphasize how imaging reveals a greater understanding of the ...
(Date:2/10/2016)... ... February 10, 2016 , ... Early this week, Team Iconic at ... of Nestlé KITKAT as the first global confectionery brand sourced from 100% sustainable cocoa. ... the quality of their product, through activities that focus on better farming, better lives ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... a full-service health care communications company offering education, research and medical media, ... practitioners and specialists working in infectious diseases. , As the all-inclusive resource ...
(Date:2/10/2016)... ... February 10, 2016 , ... MetLoop CEO Jay ... 2.0 version at the International Roofing Expo in Orlando, Florida on February 17-19. ... most advanced weather technology in the hands of consumers, roofing contractors, manufacturers and ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... (VRI) within Healthcare, recently partnered with Heart City Health Center to ... nearly 23 years, Heart City Health Center has provided the Elkhart community with ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... 10, 2016 --> --> This press ... .  --> Japan .  --> A separate press ... With submission, Shire continues to strengthen its presence ... Shire continues to strengthen its presence ... Shire continues to strengthen its presence in ...
(Date:2/10/2016)... SAN DIEGO , Feb. 10, 2016 /PRNewswire/ ... in viral gene therapy manufacturing, and Renova™ Therapeutics, a ... failure and other chronic diseases, have entered into a ... and produce cGMP-grade RT-100 (Ad5.hAC6) Drug Product for use ... --> --> This relationship will leverage ...
(Date:2/10/2016)... Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko ... completed, through its indirect wholly-owned subsidiary Laurel Acquisition Inc. ... outstanding shares of common stock of Ocata Therapeutics, Inc. ... "Ocata") for a price of US$8.50 per share net ... the Tender Offer on November 19, 2015, U.S. Eastern ...
Breaking Medicine Technology: